CF Industries (NYSE: CF) — Buy at $140 PT with May 6 Earnings Options Overlay
Equity Research | April 30, 2026 | Rating: MODERATE BUY | PT: $140 (+12%)
Header
| Price (4/30/26) | $125.00 |
| Market Cap / EV | $19.2B / $20.4B |
| Shares O/S | 153.6M |
| FY25 EBITDA | $2.89B (40.8% margin) |
| FY25 EPS | $8.97 (+33.1%) |
| ROE | 37.2% |
| EV/EBITDA (TTM) | 7.06x |
1. Executive Summary
CF is the highest-margin, highest-ROE pure-play nitrogen producer in North America, structurally advantaged by cheap Henry Hub gas at a moment when global nitrogen markets remain dislocated by the Iran conflict. Our $140 PT rests on three legs:
- Sustained nitrogen tightness — Iran disruption removed approximately 30% of globally-traded urea (per CEO at AGM)
- Section 45Q tax credits at Donaldsonville scaling to approximately $300M annual EBITDA
- Blue Point JV with JERA/Mitsui (FID confirmed) — adds approximately 1.4M tons CF-share ammonia capacity by 2028
Thesis
- Margin & ROE leadership. FY25 EBITDA margin 40.8%, ROE 37.2%. Nutrien (ROE 9.2%) and Mosaic (ROE 4.8%) are not in the same tier.
- Capital return machine. Repurchased 16.6M shares (approximately 10% of S/O) for $1.34B in 2025. Total FY25 capital return $1.7B (approximately 9% of mkt cap).
- Iran/Hormuz upside optionality.
- Structural EBITDA growth wedge the market is not pricing.
Key Risks
- China urea export resumption (latent 4-6Mt capacity)
- Hormuz fully reopens — bear case
- DOJ antitrust investigation (March 2026)
- $72M insider selling in 3 months (Bohn says retiree-driven)
- Blue Point execution risk
2. AGM Recap (April 30)
- All 11 director nominees elected
- Say-on-pay PASSED; KPMG ratified
- Shareholder Proposal #4 (golden parachutes) PASSED — governance shift
- FY25: 10.1Mt ammonia at 97% utilization, $1.7B capital returned
- Bohn quantified approximately 30% of globally-traded urea removed during Iran disruption
- Q1 2026 earnings May 6 (after-market), call May 7 — will discuss Iran impact
3. WACC = 8.4%
| Input | Value |
|---|---|
| Risk-free (10Y UST) | 4.20% |
| ERP (Damodaran) | 4.75% |
| Industry unlevered beta | 0.90 |
| Re-levered beta | 1.02 |
| Cost of equity | 9.05% |
| After-tax cost of debt | 4.45% |
| Equity / Debt weight | 85.7% / 14.3% |
| WACC | 8.4% |
4. Probability-Weighted DCF
| Scenario | Prob | $/Share | Weighted |
|---|---|---|---|
| Bear | 25% | $98.53 | $24.63 |
| Base | 50% | $138.77 | $69.39 |
| Bull | 25% | $183.75 | $45.94 |
| Weighted | $139.96 |
Rounded 12-month PT: $140.00 (+12.0%)
Base Case DCF (US$M)
| 2026E | 2027E | 2028E | 2029E | 2030E | Term | |
|---|---|---|---|---|---|---|
| EBITDA | 3,100 | 2,850 | 2,800 | 3,100 | 3,100 | 3,100 |
| NOPAT | 2,012 | 1,810 | 1,763 | 1,981 | 1,966 | 1,950 |
| Capex | (1,400) | (1,200) | (900) | (600) | (550) | (550) |
| FCFF | 802 | 850 | 1,113 | 1,621 | 1,676 | 1,680 |
EV $22,515M; Equity $21,315M; $138.77/share base
5. Reverse DCF — what the market is pricing
At $125, EV $20.4B implies steady-state EBITDA of approximately $2.55B — a 12% reversion below FY25's $2.89B. The market is paying for cyclical reversion only and giving zero credit for either 45Q (approximately $300M run-rate EBITDA) or Blue Point ($200-300M CF share by 2028-29). That asymmetry is the trade.
6. Peer Comp
| Metric | CF | NTR | MOS | Industry Median |
|---|---|---|---|---|
| Stock Price | $125.00 | $73.84 | $23.00 | — |
| EV/EBITDA (TTM) | 7.06x | 7.58x | 4.94x | 11.0x |
| P/E (TTM) | 13.9x | 15.7x | 13.6x | 15.9x |
| EBITDA Margin | 40.8% | 23.3% | 20.8% | 22.0% |
| ROE | 37.2% | 9.2% | 4.8% | 8.0% |
| Buyback Yield (2025) | approx 7% | approx 2% | approx 1% | approx 2% |
Read-across: CF trades at a discount to NTR on EV/EBITDA despite about 4x the ROE.
7. Options Strategy — May 6 Earnings Catalyst
Live data April 30, 2026 close; CF approximately $125; data via Massive market-data API.
IV Term Structure
| Expiry | DTE | ATM IV | Implied Move | Earnings IV Premium |
|---|---|---|---|---|
| May 8 | 8 | approx 66% | ±9.8% | +14 vol pts |
| May 15 | 15 | approx 62% | ±10.0% | +10 vol pts |
| May 22 | 22 | approx 60% | ±11.7% | +8 vol pts |
| Jun 18 | 50 | approx 52% | ±15.3% | Baseline |
Implied earnings move (decomposition): ±6.8% (approximately ±$8.50 from $125)
Strategy Comparison
| # | Strategy | Net Cost | Max P | Max L | BE | R/R |
|---|---|---|---|---|---|---|
| 1 | Bull call spread $125/$135 May 15 | $3.15 db | $6.85 | $3.15 | $128.15 | 2.17:1 |
| 2 | Bear put spread $120/$110 May 15 | $2.60 db | $7.40 | $2.60 | $117.40 | 2.85:1 |
| 3 | Sell $115 cash-secured put May 15 | -$2.60 cr | $260 | $11,240 | n/a | 55% APR |
| 4 | Long $130 call May 15 | $4.00 db | Unlimited | $4.00 | $134.00 | Convex |
| 5 | Long Jun 18 $130 call | $7.50 db | Unlimited | $7.50 | $137.50 | Convex |
Recommended: Bull Call Spread $125/$135
| Leg | Action | Premium |
|---|---|---|
| $125 Call | BUY | Pay $6.00 |
| $135 Call | SELL | Receive $2.85 |
| Net debit | $3.15 | |
| Max profit (CF ≥ $135) | $6.85 (+217%) | |
| Breakeven | $128.15 | |
| R/R | 2.17 : 1 |
Why Spread > Naked Call
- IV crush mitigation: vega offsetting ($101 vs $92)
- Capital efficiency: same slope, 21% lower cost
- Net theta -$0.03/day vs -$0.20/day naked
- Aligned with PT (max profit at $135-140)
CRITICAL: Dividend Trap
CF $0.50 dividend ex-date is May 15, 2026 — same day as spread expiry. Early-assignment risk on short $135 leg if CF closes >$135 on May 14.
Updated Recommendation
Bull call spread $125/$135 May 22. Same structure, about $0.35 more debit, no dividend trap. Extra week useful for digesting May 7 conference call.
8. Catalysts
- May 6 (T+6): Q1 2026 earnings + May 7 call
- Hormuz/Iran developments (track Brent + freight rates)
- China urea export policy
- Blue Point construction milestones
- DOJ investigation status
- Insider filings (watch for Bohn purchases)
9. Conclusion
MODERATE BUY, $140 PT (+12%). Market is pricing CF for cyclical reversion only — structural growth catalysts (45Q + Blue Point) are essentially free options. Tactical traders: $125/$135 May 22 bull call spread, 2.17:1 R/R, defined risk, IV crush protected.
Methodology & Disclaimer
Damodaran valuation framework: three-scenario probability-weighted DCF, WACC from industry unlevered beta, reverse DCF sanity check, peer relative valuation. Options data via Massive market-data API as of April 30, 2026 close. Macro: Iran conflict, partial Hormuz blockade, Brent $108-118, 10Y UST 4.20%.
Research-grade analysis for investment-decision purposes only. Options carry risk of total loss. Not a solicitation. Reader must form independent judgment and consult qualified advisors.
No redactions applied.
Published via wiis. Originals are encrypted at rest; this page reflects the redacted version. report abuse.
Discussion
No comments yet.